MedPath

A comparative effect of Lekhaniya Mahakashaya Ghan Vati and Mustadi Ghan Vati in the management of Dyslipidemia

Not Applicable
Completed
Conditions
Health Condition 1: E782- Mixed hyperlipidemia
Registration Number
CTRI/2017/01/007642
Lead Sponsor
Govt Akhandanand Ayurved College and Hospital Bhadra Ahmedabad
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
30
Inclusion Criteria

1.If any one or many parameters among lipid profile of an individual found to be in limit stated below,then the subject will be included in the study for objective criteria:

Serum cholesterol - 200mg/dl or more Serum triglycerides -150mg/dl or more

Serum LDL - 100mg/dl or more

Serum VLDL-10-30mg/dl or more

Serum HDL - <40mg/dl.

2.Patient’s ongoing anti-hyperlipidemic drugs will be stopped and wash out period will be specified.

3.The main signs and symptoms in the present study will be taken for subjective criteria are as follows-

weakness, Fatigue, Paraesthesia, Weight gain,

Angachalatva, Alasya, Kshudrashwas, Nidradhikya, Swedadhikya, Daurgandhya ,

Snigdhata, Atipipasa, Atikshudha, Angagaurava.

Exclusion Criteria

•Patient having age <18 or >60 yrs.

•Patient having serious cardiac problems- M.I., Cardiac Failure.

•Endocrinal disorders will not be taken for study like diabetes mellitus, hypothyroid.

•Patient having history of obesity and Hyperlipidemia due to drugs e.g. corticosteroids, Antidepressent drugs will not be taken for study.

•If Lipid profile parameters will come in very high range, patient will be excluded which is given below-

Serum cholesterol- >300mg/dl.

Serum triglycerides- >500mg/dl.

Serum LDL - >190mg/dl.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
After completion of the course of the treatment the result will be assessed on the basis of - lipid profile of patients before and after treatment and difference in the score of sign and symptoms of Medoroga and dyslipidemia.Timepoint: 6 weeks
Secondary Outcome Measures
NameTimeMethod
ILTimepoint: NI
© Copyright 2025. All Rights Reserved by MedPath